Long Covid Treatment Research Study
Researchers at BIDMC are partnering with individuals experiencing post-acute sequelae SARS-CoV-2 infection ("Long COVID") to evaluate the effect of an oral medication. Join our compensated study today!
Fast Facts
history of confirmed COVID-19 infection
post-COVID symptoms for at least 2 months
18 Years and Older
Compensation Provided
Conducted in Boston, MA
Study Background
Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) or “Long COVID”
Some people who have had COVID-19 continue to experience symptoms for a long time after they were first infected. Symptoms might reappear after initial recovery from COVID-19, or they may persist from the initial illness. Symptoms may also fluctuate or stop and start over time. This is commonly known as “long COVID”.
This research study aims to test the efficacy, safety, and tolerability of an oral medication called abrocitinib to treat long COVID.
Your participation in this study may help researchers improve treatment approaches for long COVID. Advance research today and join our compensated study!
Study Background
Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) or “Long COVID”
Some people who have had COVID-19 continue to experience symptoms for a long time after they were first infected. Symptoms might reappear after initial recovery from COVID-19, or they may persist from the initial illness. Symptoms may also fluctuate or stop and start over time. This is commonly known as “long COVID”.
This research study aims to test the efficacy, safety, and tolerability of an oral medication called abrocitinib to treat long COVID.
Your participation in this study may help researchers improve treatment approaches for long COVID. Advance research today and join our compensated study!
Additional Information
You may qualify for this study if you meet the following criteria.
Key Criteria:
- 18+ years old
- History of confirmed COVID-19 infection more than 30 days ago
- Ongoing COVID symptoms for at least 2 months that cannot be explained by another diagnosis. Symptoms may include:
- fatigue
- worsening of symptoms after even minor physical or mental activity
- joint/muscle pain
- chronic cough
- shortness of breath
- headache
- changes in smell/taste
- abnormal movement/tremor
- dizziness
- brain fog – problems thinking or concentrating
- abdominal pain
- dry mouth
- thirst
- feeling full or vomiting after eating
- diarrhea
- constipation
- chest pain
- palpitations
- decreased sexual desire or capacity
- sleep disturbance
- No other acute or chronic infections
- No history of HIV, Hepatitis B, Hepatitis C, herpes, tuberculosis, Epstein Barr Virus, immunodeficiency disorders, cancers, blood clotting disorders, heart conditions, or other chronic conditions that have caused debilitating symptoms
This study will be conducted in two parts.
Part 1: Eligible participants will be randomized to receive either abrocitinib or a placebo (sugar pill) orally every day for 84 days.
Part 2 (optional): Participants will be given the opportunity to enter into an optional Open Label Extension period, under which all self-selected participants will receive abrocitinib orally every day for another 84 days.
Part 1 includes 7 visits over 112 days. If you continue with part 1 and the optional part 2, there are 11 visits total over 196 days. The study requires in-person visits at BIDMC, where participants will provide their medical and medication history, vital signs, and symptom-directed physical exams, as well as complete questionnaires, a walk-test, and have blood drawn.
